SK6552003A3 - Condensed purine derivatives as A1 adenosine receptor antagonists and process for the preparation thereof - Google Patents

Condensed purine derivatives as A1 adenosine receptor antagonists and process for the preparation thereof Download PDF

Info

Publication number
SK6552003A3
SK6552003A3 SK655-2003A SK6552003A SK6552003A3 SK 6552003 A3 SK6552003 A3 SK 6552003A3 SK 6552003 A SK6552003 A SK 6552003A SK 6552003 A3 SK6552003 A3 SK 6552003A3
Authority
SK
Slovakia
Prior art keywords
group
substituted
alkyl
amino
compound
Prior art date
Application number
SK655-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Ko-Chung Lin
Chi Vu
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of SK6552003A3 publication Critical patent/SK6552003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
SK655-2003A 2000-12-01 2001-11-30 Condensed purine derivatives as A1 adenosine receptor antagonists and process for the preparation thereof SK6552003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
SK6552003A3 true SK6552003A3 (en) 2003-12-02

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
SK655-2003A SK6552003A3 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as A1 adenosine receptor antagonists and process for the preparation thereof

Country Status (33)

Country Link
US (2) US6605601B2 (uk)
EP (1) EP1347981B1 (uk)
JP (2) JP2004514723A (uk)
KR (1) KR20040011439A (uk)
CN (1) CN100497340C (uk)
AR (1) AR035400A1 (uk)
AT (1) ATE394402T1 (uk)
AU (2) AU2002219977B2 (uk)
BG (1) BG107849A (uk)
BR (1) BR0115833A (uk)
CA (1) CA2430508C (uk)
CZ (1) CZ20031513A3 (uk)
DE (1) DE60133931D1 (uk)
EA (1) EA009814B1 (uk)
EE (1) EE200300260A (uk)
ES (1) ES2305139T3 (uk)
GE (1) GEP20094697B (uk)
HK (1) HK1059927A1 (uk)
HU (1) HUP0400530A3 (uk)
IL (1) IL156046A0 (uk)
IS (1) IS6821A (uk)
MX (1) MXPA03004857A (uk)
MY (1) MY127120A (uk)
NO (1) NO20032483L (uk)
NZ (1) NZ526511A (uk)
PL (1) PL362642A1 (uk)
SK (1) SK6552003A3 (uk)
TR (1) TR200300766T2 (uk)
TW (1) TWI293301B (uk)
UA (1) UA75625C2 (uk)
WO (1) WO2002044182A1 (uk)
YU (1) YU42903A (uk)
ZA (2) ZA200304067B (uk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
YU42903A (sh) * 2000-12-01 2006-05-25 Biogen Inc. Kondenzovani derivati purina kao antagonisti a1 receptora adenozina
US7202252B2 (en) * 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
NZ543109A (en) 2003-04-25 2008-06-30 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
EP1637532A1 (en) * 2003-04-25 2006-03-22 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivative
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
CA2601032A1 (en) * 2005-03-11 2006-09-21 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
WO2007117549A2 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
WO2007137030A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
CA2656002A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
CA2656039A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
CA3087655A1 (en) 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
CA2028235C (en) 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
CA2418125C (en) 1991-09-23 2007-12-04 Florida State University Beta-lactams useful in the preparation of substituted isoserine esters
WO1998015555A1 (fr) * 1996-10-07 1998-04-16 Kyowa Hakko Kogyo Co., Ltd. Derives de purine fondue
EP1014995A4 (en) * 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
US6489331B1 (en) * 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
YU42903A (sh) * 2000-12-01 2006-05-25 Biogen Inc. Kondenzovani derivati purina kao antagonisti a1 receptora adenozina

Also Published As

Publication number Publication date
CZ20031513A3 (cs) 2003-09-17
EP1347981B1 (en) 2008-05-07
AR035400A1 (es) 2004-05-26
BG107849A (bg) 2004-01-30
AU1997702A (en) 2002-06-11
EA200300629A1 (ru) 2003-12-25
EA009814B1 (ru) 2008-04-28
NO20032483D0 (no) 2003-06-02
MY127120A (en) 2006-11-30
CN1481387A (zh) 2004-03-10
WO2002044182A1 (en) 2002-06-06
US6605601B2 (en) 2003-08-12
NZ526511A (en) 2005-04-29
HK1059927A1 (en) 2004-07-23
US7022686B2 (en) 2006-04-04
ZA200408755B (en) 2005-07-27
US20020111333A1 (en) 2002-08-15
EE200300260A (et) 2003-08-15
US20030220358A1 (en) 2003-11-27
JP2010053148A (ja) 2010-03-11
DE60133931D1 (de) 2008-06-19
CN100497340C (zh) 2009-06-10
HUP0400530A3 (en) 2007-05-29
MXPA03004857A (es) 2003-08-19
TR200300766T2 (tr) 2004-09-21
CA2430508A1 (en) 2002-06-06
EP1347981A1 (en) 2003-10-01
AU2002219977B2 (en) 2008-01-24
IS6821A (is) 2003-05-20
ZA200304067B (en) 2005-05-30
CA2430508C (en) 2010-05-18
PL362642A1 (en) 2004-11-02
TWI293301B (en) 2008-02-11
JP2004514723A (ja) 2004-05-20
ES2305139T3 (es) 2008-11-01
HUP0400530A2 (hu) 2004-06-28
ATE394402T1 (de) 2008-05-15
NO20032483L (no) 2003-07-30
BR0115833A (pt) 2003-10-28
UA75625C2 (en) 2006-05-15
IL156046A0 (en) 2003-12-23
YU42903A (sh) 2006-05-25
GEP20094697B (en) 2009-06-10
KR20040011439A (ko) 2004-02-05

Similar Documents

Publication Publication Date Title
JP2010053148A (ja) Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体
JP5014120B2 (ja) 酸化窒素生物活性を有する活性酸素生成酵素阻害剤およびそれらの使用
AU2002219977A1 (en) Condensed purine derivatives as A1 adenosine receptor antagonists
JP2988711B2 (ja) 縮合プリン誘導体
TWI615144B (zh) 隻重選擇性ＰＩ３δ及γ激酶抑制劑
AU2007220047B2 (en) Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
TW201542211A (zh) 使用齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）或其類似物治療和預防內皮功能障礙之方法
BG65720B1 (bg) Полициклоалкилпурини, антагонисти на аденозин рецептор
WO2014127331A1 (en) Novel uses
AU2002341618B2 (en) Methods of treating pulmonary disease
SK6622002A3 (en) Adenosine receptor antagonists and methods of making and using the same
JP3181305B2 (ja) 選択的アデノシン受容体アゴニスト及びアンタゴニスト
DE69029303T2 (de) 5-Triazolo(3,4-i)purinderivate
KR20090042330A (ko) 혈액뇌장벽을 통과하지 않는 ｋｗ―３９０２ 컨쥬게이트
NO311920B1 (no) Xantinderivater som adenosin-A1-reseptorantagonister
US5015647A (en) Method for treating viral infections
US5017577A (en) Methods for treating viral infection
US5173492A (en) s-Triazolo(3,4-I)purine derivatives
CN117924280B (zh) 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途
CN118217290B (zh) 可溶性鸟苷酸环化酶刺激剂在防治高原肺水肿中的用途
DE10137038A1 (de) N-3,7 Substituted 1-Methylxanthine Derivates Displaying Inhibitory Activites on Type Five Phosphodiesterase
CN118217290A (zh) 可溶性鸟苷酸环化酶刺激剂在防治高原肺水肿中的用途
JPH07316158A (ja) プリン誘導体及び炎症性疾患の抑制剤

Legal Events

Date Code Title Description
FC9A Refused patent application